Rigel Pharmaceuticals, Inc.
RIGL
$42.58
$1.794.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 229.08% | 879.70% | 1,999.08% | 2,819.35% | 787.33% |
| Total Depreciation and Amortization | 9.19% | -0.99% | 8.39% | 26.13% | 51.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -653.42% | -2,868.06% | -2,463.40% | -355.59% | -376.43% |
| Change in Net Operating Assets | -364.76% | -14.40% | -12,852.94% | -183.36% | 52.60% |
| Cash from Operations | 20.60% | 122.73% | 140.40% | 535.51% | 634.74% |
| Capital Expenditure | 100.00% | 100.00% | 100.00% | -280.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -47.06% | -25.76% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -19.65% | -1,220.99% | -2,370.53% | -1,069.06% | -1,437.31% |
| Cash from Investing | -19.83% | -1,233.16% | -2,336.44% | -1,053.70% | -1,380.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 271.64% | 236.50% | 312.47% | 573.91% | 202.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 46.96% | -- | -- | 100.00% | -123.06% |
| Cash from Financing | -206.64% | -24.95% | 105.16% | 152.60% | -104.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -57.45% | -205.47% | -167.23% | -149.39% | 236.46% |